Aim of the study. The 4C Mortality Score was created to predict mortality in hospitalised patients with COVID-19 and has to date been evaluated only in respiratory system disorders. The aim of this study was to investigate its application in patients with COVID-19-associated acute ischaemic stroke (AIS).Clinical rationale for study. COVID-19 is a risk factor for AIS. COVID-19-associated AIS results in higher mortality and worse functional outcome. Predictors of functional outcome in COVID-19-associated AIS are required. Materials and methods.This was a retrospective observational study of patients with AIS hospitalised in seven neurological wards in Małopolska Voivodship (Poland) between August and December 2020. We gathered data concerning the patients' age, sex, presence of cardiovascular risk factors, type of treatment received, and the presence of stroke-associated infections (including pneumonia, urinary tract infection and infection of unknown source). We calculated 4C Mortality Score at stroke onset, and investigated whether there was a correlation with neurological deficit measured using the National Health Institute Stroke Scale (NIHSS) and functional outcome assessed using the modified Rankin Scale (mRS) at discharge. Results.The study included 52 patients with COVID-19-associated AIS. The 4C Mortality Score at stroke onset correlated with mRS (r s = 0.565, p < 0.01) at discharge. There was also a statistically significant difference in the mean 4C Mortality Score between patients who died and patients who survived the stroke (13.08 ± 2.71 vs. 9.85 ± 3.47, p = 0.04).Conclusions and clinical implications. 4C Mortality Score predicts functional outcome at discharge in COVID-19-associated AIS patients.
Introduction: Epilepsy is one of the most common diseases of the central nervous system. According to the World Health Organization, it accounts for 1% of the global burden of disease worldwide. Pharmacotherapy remains the primary therapeutic tool in this disease. However, more and more emphasis is placed on approaching this group of patients in an interdisciplinary manner, taking their various needs into account: social, professional, economic or psychological. Attention is also paid to the positive impact of physical activity on the quality of life of patients with epilepsy. The patients with diagnosed epilepsy often complain of a feeling of instability not reflected in standard neurological examination. Early detection of postural control disorders is possible using an objective research tool which is the modified CTSIB test (Clinical Test of Sensory Interaction and Balance). Aim of the study: The aim of the study was to assess the influence of targeted physical therapy on the quality of life among patients with diagnosed epilepsy of unknown etiology using the SF-36 quality of life questionnaire. Materials and methods: The study included 11 professionally active adults with diagnosed generalized epilepsy of unknown etiology, treated at the Department or Outpatient Clinic of Neurology at John Paul II Specialist Hospital in Kraków. Finally, out of the 11 recruited patients (5 women and 6 men), 1 patient was excluded from the study due to a history of craniocerebral trauma. Patients were examined 3 times every month using EEG and the SF-36 quality of life questionnaire. Additionally, between the 2nd and the 3rd month of the pilot study, the study group underwent physical therapy focused on balance disorders using the Biodex SD stabilometric platform. Results: Overall, the quality of life index measured using the SF-36 quality of life questionnaire in the study group improved after the completion of targeted physical therapy. Conclusions: 1. Generalized epilepsy of unknown etiology results in a significant deterioration in the quality of life of patients, which may also be accompanied by disorders of postural control. 2 A targeted program of physiotherapy in the treatment of patients with generalized epilepsy of unknown etiology may has a positive effect on their quality of life. null
Introduction: Epilepsy is a chronic disease characterised by a predisposition to the occurrence of recurrent and unprovoked seizures. Due to the unpredictability of the disease (due to the possibility of seizures occurring at any time), the quality of life of these patients is drastically reduced. Stigmatisation of patients with epilepsy is common all over the world and concerns not only developing countries, but also those already highly developed. Patients with epilepsy show less activity in many areas of everyday life, including physical activity (they exercise less than the general public), and also have a lower level of mobility. This may be a significant factor contributing to the observation of balance disorders this group (from discrete, unnoticeable by them and the environment, to clinically manifesting instability of posture). So far, however, this has not been possible to clearly document, and to date, the standards for rehabilitation in this group of patients have not been established. However, it is widely known that balance disorders, apart from epileptic seizures, decrease quality of life.In the control of postural disorders, the co-ordination of the visual, somatosensory and vestibular systems is necessary. The cortical representation of the visual and sensory systems can be analysed during electroencephalographic recording. Additionally, the Biodex Balance SD stabilometric platform is an objective tool used to confirm imbalances. The application of this diagnostic device allows to quickly determine the exact type of imbalance that can subsequently undergo targeted physiotherapy. Research objective: The aim of the study was to assess the impact of targeted physiotherapy in a group of patients diagnosed with epilepsy of unknown etiology and balance disorders. Materials and methods: Patients diagnosed with generalised epilepsy of unknown etiology took part in the study. They were treated at the neurology ward or clinic of John Paul II Specialist Hospital in Krakow. The patients were examined 3 times at monthly intervals using the following methods: - EEG testing, - SF-36 quality of life questionnaire, - Biodex SD stabilometric platform. In addition, between the 2nd and 3rd months of the study, the patients underwent physiotherapy for balance disorders (3 times a week for 1 month, each session lasting 30 minutes). Results: In 10 patients who were subjected to selective physiotherapy using the Biodex SD stabilometric platform, objective improvement in balance stability was noted. All patients also reported oral improvement in the sense of postural stability after the completion of the rehabilitative treatment. Conclusions: Targeted physiotherapy in a group of patients with diagnosed epilepsy of undetermined etiology, and accompanying balance disorders has a positive impact on their daily functioning.
Kwetiapina jest pochodną benzotiazepiny zaliczaną do atypowych leków neuroleptycznych, która w chorobie Parkinsona znajduje zastosowanie w przypadku współistniejących objawów psychotycznych. Chociaż lek jest dobrze tolerowany jego zastosowanie zwłaszcza u pacjentów w podeszłym wieku może wiązać się z różnymi działaniami niepożądanymi. Celem pracy było ustalenie związku pomiędzy wystąpieniem afazji czuciowo – ruchowej u chorego z chorobą Parkinsona i współistniejącymi zaburzeniami psychotycznymi a stosowaniem kwetiapiny. Przedstawiamy przypadek 64 – letniego chorego z rozpoznaną chorobą Parkinsona i współistniejącymi zaburzeniami zachowania w czasie snu REM (RBD) potwierdzonymi w badaniu polisomnograficznym, u którego zastosowanie w terapii dodanej z powodu zaburzeń psychotycznych kwetiapiny (w dawce 50 mg/ dobę) spowodowało wystąpienie zaburzeń mowy o typie afazji mieszanej czuciowo- ruchowej. Afazja wystąpiła w czwartej dobie od rozpoczęcia leczenia atypowym neuroleptykiem. W badaniu MRI głowy nie stwierdzono ,,świeżego'' niedokrwienia mózgowia. W badaniu video- eeg nie zarejestrowano ogniskowego stanu padaczkowego. Całkowite wyleczenie nastąpiło po odstawieniu kwetiapiny. W związku z powyższym jako przyczynę ogniskowych zaburzeń neurologicznych przyjęto efekt uboczny leczenia kwetiapiną.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.